Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Approved
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Alzheimer Disease
Mechanism of Action
Anti-Amyloid Antibody
Clinical Trial
NCT03887455Last updated: 12/3/2025
Leqembi
Leqembi is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E 4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology (see section 4.4).
View on EMA